Hank, as an experienced industry professional
What do YOU think SGP is attempting to accomplish with their Zonagen partnership.
SGP outbid 4 other major pharmaceutical companies to acquire the rights to Vasomax. Prior to doing this, I'm certain that they did a great amount of due diligence. They must have had full access to all the data from all the clinical trials - patient & MD related, any work that Zonagen did, manufacturing information, etc. They undoubtedly spoke with many, if not all, of the MD's participating in the trial. Finally, they certainly examined the patent status. I assume that the folks at SGP are fairly competent, as are you. How can you be so certain that there's no potential here when they obviously came to a completely different opinion.
First of all, I doubt they would do ANYTHING unless they felt secure about the patent status. Furthermore, since their initial milestone payment of $10 M, they have continued to work on the project, burning considerable dollars in preparing the NDA for filing. Why do YOU think they committed this colossal blunder by filing in Mexico before the USA?? It doesn't make any sense to me why they would continue with the whole project. If they felt that they made a mistake at the outset, why file in a foreign country?? Wouldn't they just fold up their tent to minimize their losses?? I have medical device, not pharmaceutical industry experience but this doesn't fit in any pattern of behavior for a big company that I've ever seen.
Finally, what is your function at your company - science, marketing, regulatory.....? |
